Actively Recruiting
Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases
Led by Peking Union Medical College Hospital · Updated on 2022-08-16
200
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
With the growth of China's economy and changes in diet, metabolic diseases like hypertension, diabetes, hyperuricemia, and obesity have become major health concerns, leading to chronic kidney disease (CKD). Researchers are studying how these diseases cause kidney damage through mechanisms such as hormone system activation, blood vessel dysfunction, oxidative stress, and inflammation. The study aims to create a patient group with CKD caused by metabolic diseases to find risk factors for disease progression and identify early diagnostic and treatment biomarkers. Participants will be grouped based on their primary metabolic condition: hypertension, diabetes, hyperuricemia, or obesity. The study will collect blood, urine, and imaging data to detect biomarkers that might help in early diagnosis and predict disease outcomes. This is an observational study, meaning participants will be monitored without receiving specific treatments from the study. During the 3-year study, participants will be regularly assessed for kidney function decline, complications of CKD, cardiovascular events, and overall health quality using tools like the SF-36 questionnaire and the Mini-Mental State Examination (MMSE). Researchers will also track serious outcomes such as progression to end-stage renal disease and death. The study involves ongoing observation to better understand disease progression and improve early detection methods.
CONDITIONS
Brief Title
Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with metabolic diseases such as hypertension, diabetes, hyperuricemia, or obesity
- Able to understand the research process
- Willing to volunteer and able to sign informed consent
You will not qualify if you...
- Younger than 18 years or older than 80 years
- Patients with primary or secondary glomerular diseases
- Patients with kidney conditions like cysts, polycystic kidney disease, medullary sponge kidney, hydronephrosis, renal artery stenosis, renal vein thrombosis, or tumors
- Contraindications to MRI examination
- Pregnant or breastfeeding patients
- Patients with unstable vital signs, organ failure, or confusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 3 years
Participants undergo blood, urine, and imaging biomarker assessments for early diagnosis and prognosis prediction.
Duration - 3 years
Participants are monitored for kidney disease progression, cardiovascular events, and overall health outcomes over 3 years.
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
Y
Yan Liu
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here